Loading
Etoposide / Atezolizumab / Small Cell Lung Cancer · Phase 3 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 3 trial comparing lurbinectedin plus atezolizumab against atezolizumab monotherapy as maintenance treatment in extensive-stage small-cell lung cancer after induction therapy. No outcome data are reported in this registry record; the study is actively enrolling or has completed enrollment but results are not yet posted.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Small-Cell Lung Cancer; age from 18 Years. Intervention: Arm A: Atezolizumab+Lurbinectedin. Compared with: Arm B: Atezolizumab — Active Comparator. n = 660. 93 sites across 13 countries.
This is a registered Phase 3 trial comparing lurbinectedin plus atezolizumab against atezolizumab monotherapy as maintenance treatment in extensive-stage small-cell lung cancer after induction therapy. No outcome data are reported in this registry record; the study is actively enrolling or has completed enrollment but results are not yet posted.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Once results are published, this trial will provide evidence on whether adding lurbinectedin to atezolizumab maintenance improves survival outcomes in ES-SCLC. Clinicians should await peer-reviewed publication of results before considering changes to maintenance practice.
This is a clinical trial registry record for an active Phase 3 study with no results posted; the record describes planned design and enrollment only.
As stated by the source record.
Quoted from the source exactly as published.
Once results are published, this trial will provide evidence on whether adding lurbinectedin to atezolizumab maintenance improves survival outcomes in ES-SCLC. Clinicians should await peer-reviewed publication of results before considering changes to maintenance practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05091567). This is a study registration, not published results. Lead sponsor: Hoffmann-La Roche. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 660 participants (ACTUAL). Conditions: Small-Cell Lung Cancer. Interventions: DRUG: Atezolizumab; DRUG: Lurbinectedin; DRUG: Carboplatin; DRUG: Etoposide. Primary outcome measures: Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS) , Up to 26 months; Randomized Phase: Overall Survival (OS) , Up to 26 months. Brief summary: Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab induction treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.